WHO ICTRP trial
PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic…
EUCTR2016-001676-29-IT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2016-001676-29-IT |
|---|---|
| Public title | PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgery |
| Scientific title | PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgery - PROMO |
| Primary sponsor | OSLO UNIVERSITETSSYKEHUS HF |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Norway;Italy |
| Conditions | Osteosarcoma, not eligible for curative surgery MedDRA version: 20.0 Level: PT Classification code 10031291 Term: Osteosarcoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA… |
| Interventions | Trade Name: KEYTRUDA - 50 MG- POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO) 1 FLACONCINO Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: PEMBROLIZUMAB CAS Number… |
| Registration date | Feb 27, 2018 |
| Target size | 25 |
| Secondary IDs | MK3475_PROMO;PROMO |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: